DeepCyte, a Delaware and Denmark-based techbio company building AI toxicology tools for drug development, has raised $1.5 million in Seed funding.
Investors
Backed by medtech executive and investor Carl J. G. Evertsz, who will serve as Chairman of the Board.
DeepCyte Use of Funds
The company will use funding to develop and scale its AI and single-cell metabolomics platforms.
About DeepCyte
Led by CEO Theodore Alexandrov, DeepCyte focuses on transforming drug development through AI-driven toxicology at single-cell resolution. Its platform combines advanced metabolomics and machine learning to detect, predict, and explain drug toxicity in human cells with unprecedented precision. The company is leveraging its proprietary technologies, including MetaCore for high-throughput single-cell metabolomics and DeeImmuno for AI-based toxicity prediction. Headquartered in Delaware and Copenhagen, DeepCyte’s mission is to reveal and prevent toxicity in every cell, at scale, before drugs reach patients.
Funding Details
Company: DeepCyte, Inc.
Raised: $1.5M
Round: Seed
Funding Date: April 2026
Investor: Carl J. G. Evertsz
Company Website: https://www.deepcyte.bio/
Software Category: AI Drug Discovery / Toxicology
Source: https://www.prnewswire.com/news-releases/deepcyte-raises-1-5m-to-bring-single-cell-ai-toxicology-to-drug-development-302737632.html